首页> 美国卫生研究院文献>Molecules >Synthesis Docking and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo321-ijQuinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa
【2h】

Synthesis Docking and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo321-ijQuinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa

机译:Pyrrolo 321-ij Quinolin-2(1H)-作为因子Xa和XIa新抑制剂的杂合物的合成对接和体外抗凝血活性测定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Coagulation factor Xa and factor XIa are proven to be convenient and crucial protein targets for treatment for thrombotic disorders and thereby their inhibitors can serve as effective anticoagulant drugs. In the present work, we focused on the structure–activity relationships of derivatives of pyrrolo[3,2,1- ]quinolin-2(1 )-one and an evaluation of their activity against factor Xa and factor XIa. For this, docking-guided synthesis of nine compounds based on pyrrolo[3,2,1- ]quinolin-2(1 )-one was carried out. For the synthesis of new hybrid hydropyrrolo[3,2,1- ]quinolin-2(1 )-one derivatives, we used convenient structural modification of both the tetrahydro- and dihydroquinoline moiety by varying the substituents at the C positions. In vitro testing revealed that four derivatives were able to inhibit both coagulation factors and three compounds were selective factor XIa inhibitors. An IC value of 3.68 μM for was found for the best factor Xa inhibitor and 2 μM for the best factor XIa inhibitor.
机译:凝血因子Xa和凝血因子XIa被证明是治疗血栓性疾病的方便且至关重要的蛋白质靶标,因此它们的抑制剂可以用作有效的抗凝药物。在目前的工作中,我们重点研究了吡咯并[3,2,1-]喹啉-2(1)-one衍生物的构效关系,并评估了它们对Xa和XIa因子的活性。为此,进行了基于吡咯并[3,2,1-]喹啉-2(1)-1的九种化合物的对接导向合成。为了合成新的杂氢吡咯并[3,2,1-]喹啉-2(1)-one衍生物,我们通过改变C位置的取代基对四氢和二氢喹啉部分进行了方便的结构修饰。体外测试表明,四种衍生物能够同时抑制凝血因子,而三种化合物是选择性因子XIa抑制剂。最佳Xa因子抑制剂的IC值为3.68μM,最佳XIa因子抑制剂的IC值为2μM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号